Multiple studies have shown that inhibitors of GSK3β may be able to help normalize abnormal levels of both LTP and LDP in the brain, as treatment with GSK3β inhibitors was accompanied by increased cognitive abilities in mouse models with Fragile X syndrome, and Down syndrome, and AD [189,190,191,192,193]. The gene discussed is GSK3B; the disease is Down syndrome.